A new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE)* compared to those treated with a sulphonylurea (SU).¹

Diabetics who experience low blood sugar attacks while driving are the focus of a new health campaign launched by TREND, a diabetes nursing group together with the Automobile Association (AA) and MSD Diabetes.

Sevikar HCT®▼ simplifies treatment and could improve the management of hypertension

Panasonic have announced the European availability of its innovative ultrasound tool for personalized preventive medicine, the CardioHealth Station.

NICE has today (Wednesday 9 November) opened a consultation on new draft guidance on identifying people at high risk of developing type 2 diabetes and the provision of clinically and cost effective interventions to help reduce the risk or delay the onset of the condition.

One in four people (25 per cent) with diabetes in the UK could be at risk of amputation because they have not received a foot check in the last year, according to a new survey by Diabetes UK.

PCTs now have three months to make this life-saving treatment available as an option for physicians and their patients.

AstraZeneca has announced that the National Institute for Health and Clinical Excellence (NICE) has recommended the use of the novel antiplatelet medicine, Brilique™ (ticagrelor) by the National Health Service (NHS) in England and Wales^1,2.

NICE has published an updated guideline on the diagnosis and treatment of high blood pressure (hypertension).

Exenatide for prolonged release delivers glycaemic control in a single weekly dose